麻豆传媒

The recent Miami Breast Cancer Conference was a combined virtual and live meeting, providing an opportunity for breast cancer specialists from all disciplines to learn about emerging therapeutic strategies that they can translate into clinical practice.

In this exclusive 麻豆传媒 video, conference co-chair , of the University of Texas MD Anderson Cancer Center in Houston, briefly touches upon highlights from the meeting.

Following is a transcript of his remarks:

Let's start with the area of early-stage breast cancer and new data on gene profiling. This has been a big advance because we now have a reliable trial that tells us the outcomes of patients based on gene profiling with the 21-gene recurrence score that now, for one to three positive nodes, that the Oncotype DX score is useful in making decisions in this group of patients, particularly in postmenopausal patients. We can now spare chemotherapy for patients with one to three nodes that have lower scores, and this is really a new change.

In the area of genomics for advanced breast cancer, likewise we are seeing many new drugs being developed that are based on the results of this assay, HER2 mutations, for example, and how we treat those and where the field is going. What should we know about genomic testing in general, how to order it, how to interpret it, how to make decisions, and how to screen for clinical trials.

In the area of HER2-positive cancer, we have seen the most dramatic results from a randomized trial comparing what used to be the best second-line therapy, T-DM1 [trastuzumab emtansine; Kadcyla], to a new antibody-drug conjugate known as trastuzumab deruxtecan [Enhertu], showing almost a fourfold improvement in progression-free survival, something we have not seen before. So this is really going to turn things upside down in the HER2-positive world. But at the same time, there are new medications that are entering clinical trials as well that will continue to change things in that area.

In triple-negative breast cancers, the world of immunotherapy continues to change and evolve as we now for the first time have a recent approval of immunotherapy for early-stage breast cancer in the neoadjuvant setting.

And then, finally, controversial areas with our very well known crossfire series looking at whether immunotherapy should be used in patients with complete pathologic responses and several other complicated and controversial areas.

So, overall, an entertaining and fun way to learn and to take what you gather from the meeting and apply it on Monday morning in your practice.

Comment